In addition to the RNA interference therapies and anti-ANGPTL3 monoclonal antibodies mentioned above, therapeutic gene editing aimed at inducing permanent loss-of-function mutations in ANGPTL3 represents another approach to lowering TG levels and reducing the risk of coronary heart disease (77). This evidence concerns the gene ANGPTL3 and coronary artery disorder.